Clinical Trial

First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-30.
Trial Details
NCT Number NCT07686068
Lead Sponsor VelaVigo Bio Inc
Conditions Participants With Advanced Solid Tumor Malignancies
Enrollment 260 participants
Start Date 2026-08-18
Primary Completion 2028-12-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09